Back
Corporate News
Morepen Laboratories reports record Rs 575.31 crore quarterly revenue, CDMO mandate commercializing
04-Aug-2026, 03:23
Morepen Laboratories Limited announced its highest-ever quarterly revenue of Rs 575.31 crore and earnings for the quarter ended June 30, 2026, alongside a 207% increase in EBITDA and a 394% rise in profit after tax. The company’s CDMO mandate, valued at Rs 825 crore, has entered full-scale commercialization, with Rs 58 crore in commercial dispatches completed during the quarter, supported by a 31% growth in the API business and 19% growth in the medical devices business.
Morepen Laboratories Limited announced its highest-ever quarterly revenue of Rs 575.31 crore and earnings for the quarter ended June 30, 2026, alongside a 207% increase in EBITDA and a 394% rise in profit after tax. The company’s CDMO mandate, valued at Rs 825 crore, has entered full-scale commercialization, with Rs 58 crore in commercial dispatches completed during the quarter, supported by a 31% growth in the API business and 19% growth in the medical devices business.